Dr. Frank van Leth
Rifapentine access in Europe: growing concerns over key tuberculosis treatment component
Pathogen-free diagnosis of tuberculosis
Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model.
Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings.
The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis through European cooperation.
Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries
Relapse-free cure from multidrug-resistant tuberculosis in Germany
Time to revise WHO-recommended definitions of MDR-TB treatment outcomes
Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria
Treatment outcomes of MDR-TB and HIV co-infection in Europe
Tuberculosis Treatment Outcomes in Europe: Based on Treatment Completion, Not Cure
Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe
Treatment Outcomes in Multidrug-Resistant Tuberculosis
Viral Load and Risk of Tuberculosis in HIV Infection
More on Treatment Outcomes in Multidrug-Resistant Tuberculosis
Numbers needed to treat to prevent tuberculosis
Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey
Multidrug-resistant tuberculosis in europe, 2010-2011
Risk assessment of tuberculosis in immunocompromised patients. A TBNET study
Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement